Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia

In brief

Individuals with schizophrenia are three times as likely to smoke cigarettes as individuals without schizophrenia. While a great deal of research has been focused on smoking cessation programs for healthy individuals, little attention has been directed towards developing an effective smoking cessation treatment for schizophrenics. This project will evaluate the effects of 0, 21 and 42 mg transdermal nicotine on smoking, urge to smoke, and nicotine withdrawal symptoms after 5 hrs abstinence in smokers with schizophrenia and heavy-smoking non-psychiatric control smokers.

Key facts

Study ID

NCT00218218

Run by

National Institute on Drug Abuse (NIDA)

People needed

48

Starts

2002-06-01

Expected to finish

2005-02-01

Last updated by the study team

2017-01-12

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Smokes between 20 and 50 cigarettes per day
• Diagnosis of schizophrenia or schizoaffective disorder

You may not qualify if…

• If enrolled in the control group, must not be diagnosed with a psychiatric disorder
• Currently dependent on alcohol or any drug (other than nicotine)
• Currently trying to quit smoking
• Currently taking bupropion, desipramine, clonidine, buspirone, or doxepin
• History of liver disease
• History of heart attacks or chest pain
• Allergic to adhesives
• Pregnant or breastfeeding

Where it is running

• Providence VA Medical Center — Providence, Rhode Island, United States
• Brown University — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.